GlassScriptPhysician profile
Hamza Ismail
NPI 1962693903
$1,059.03
in general payments reported to CMS, 2019-2025
23 companies · $189 in 2025
The $189 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.21 · 2020: $49.32 · 2021: $80.72 · 2022: $399 · 2023: $166 · 2024: $124 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $479.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $226.63 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $128.08 | 2021-2024 | |
| Abbott Laboratories | $107.94 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $89.36 | 2022-2023 | Shingrix, Arexvy |
| Abbvie INC. | $57.06 | 2023-2024 | |
| Amgen INC. | $52.73 | 2021-2022 | |
| Lilly USA, LLC | $45.18 | 2021-2024 | Mounjaro |
| Pfizer INC. | $41.37 | 2025 | |
| Boston Scientific Corporation | $41.35 | 2019-2025 | Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.59 | 2022-2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.54 | 2022-2023 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $25.97 | 2024 | Strensiq |
| Antares Pharma, INC. | $23.66 | 2022 | |
| Xeris Pharmaceuticals, INC. | $22.47 | 2023 | Gvoke Hypopen |
| Astellas Pharma US INC | $18.50 | 2023 | Myrbetriq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $18.14 | 2025 | |
| Janssen Pharmaceuticals, INC | $15.88 | 2022 | |
| Sumitomo Pharma America, INC. | $14.82 | 2023 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $14.17 | 2025 | Eliquis |
| Sunovion Pharmaceuticals INC. | $14.17 | 2019 | |
| Dexcom, INC. | $12.61 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.56 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamza Ismail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.